Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
Details for the Company's cell therapy presentations are as follows:
Title: Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Session Title and Location: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II; Halls G-H
Session Date/ Time:
Publication Number: 3479
Title: A Tumor-Bearing Murine Xenograft Model as a Bioassay for Assessing CAR-T Product Potency Shows Positive Predictive Value for Clinical Performance
Session Title and Location: 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster; Halls G-H
Session Date/ Time:
Publication Number: 2293
Details for the Company's gene therapy presentation are as follows:
Title: Effective Gene Therapy for Hemophilia A: Novel Re-Dosable Non-Viral Formulation That Provides Stable, and Durable FVIII Expression with Improved Tolerability
Session Title and Location: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I; Halls G-H
Presentation Date/ Time:
Publication Number: 1232
A fourth abstract on the editing efficiency of the in vivo Cas-CLOVER™ Site-Specific Gene Editing System and off-target activity in human hepatocytes has been selected for publication in the November supplemental issue of the ASH journal Blood.
All abstracts are available on the ASH website at www.hematology.org.
P-BCMA-ALLO1 is an allogeneic CAR-T product candidate licensed to Roche targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma in Phase 1 development. This allogeneic program includes a VH-based binder that targets BCMA and has shown early evidence of encouraging safety and efficacy. Additional information about the Phase 1 study is available at www.clinicaltrials.gov using identifier: NCT04960579.
P-FVIII-101 is a liver-directed gene therapy partnered combining
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-the-65th-ash-annual-meeting-and-exposition-301974989.html
Investor Contact: Alex Lobo, Stern Investor Relations, IR@poseida.com; Media Contact: Sarah Thailing, Senior Director, Corporate Communications and IR, Poseida Therapeutics, Inc., PR@poseida.com